专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08748604B2 Process for stereoselective synthesis of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine 失效
标题翻译：立体选择性合成5-氟-1-（2R，5S） - [2-（羟甲基）-1,3-氧硫杂环戊烷-5-基]胞嘧啶的方法
公开(公告)号：US08748604B2
公开(公告)日：2014-06-10
申请号：US13582513
申请日：2011-02-25
申请人： Prakash Bhimaji Kshirsagar , Satish Manohar Bhoge , Santosh Richhariya , Kaptan Singh
发明人： Prakash Bhimaji Kshirsagar , Satish Manohar Bhoge , Santosh Richhariya , Kaptan Singh
IPC分类号： C07D239/22
CPC分类号： C07D411/04
摘要： The present invention provides an improved process for stereoselective preparation of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine and pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了5-氟-1-（2R，5S） - [2-（羟甲基）-1,3-氧硫杂环戊烷-5-基]胞嘧啶及其药学上可接受的盐的立体选择性制备的改进方法。

2. 发明申请

US20130072681A1 PROCESS FOR STEREOSELECTIVE SYNTHESIS OF 5-FLUORO-1-(2R,5S)-[2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]CYTOSINE 失效
标题翻译： 5-氟-1-（2R，5S） - [2-（羟基甲基）-1,3-氧硫杂环戊烷-5-YL]胞嘧啶的立体选择性合成方法
公开(公告)号：US20130072681A1
公开(公告)日：2013-03-21
申请号：US13582513
申请日：2011-02-25
申请人： Prakash Bhimaji Kshirsagar , Satish Manohar Bhoge , Santosh Richhariya , Kaptan Singh
发明人： Prakash Bhimaji Kshirsagar , Satish Manohar Bhoge , Santosh Richhariya , Kaptan Singh
IPC分类号： C07D411/04
CPC分类号： C07D411/04
摘要： The present invention provides an improved process for stereoselective preparation of 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine and pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了5-氟-1-（2R，5S） - [2-（羟甲基）-1,3-氧硫杂环戊烷-5-基]胞嘧啶及其药学上可接受的盐的立体选择性制备的改进方法。

3. 发明申请

US20120208787A1 CRYSTALLINE FORM OF FOSAMPRENAVIR CALCIUM 审中-公开
标题翻译： FOSAMPRENAVIR CALCIUM的结晶形式
公开(公告)号：US20120208787A1
公开(公告)日：2012-08-16
申请号：US13379926
申请日：2010-06-29
申请人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Kaptan Singh
发明人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Kaptan Singh
IPC分类号： A61K31/665 , A61P31/18 , C07F9/655
CPC分类号： C07F9/65515 , A61K31/665 , A61K2300/00
摘要： The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium.
摘要翻译：本发明涉及福沙那韦钙的结晶形式。本发明的结晶形式被称为福沙那韦钙的形式II。本发明还涉及一种制备福沙那韦钙的晶型II的方法。本发明进一步涉及一种药物组合物，其包含福沙那韦晶体钙的晶型II。本发明进一步涉及一种使用镰刀菌镰刀菌的晶型II治疗HIV感染的方法。

4. 发明授权

US09085592B2 Process for the preparation of fosamprenavir calcium 有权
标题翻译：制备福沙那韦钙的方法
公开(公告)号：US09085592B2
公开(公告)日：2015-07-21
申请号：US13496281
申请日：2010-09-16
申请人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Kaptan Singh
发明人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Kaptan Singh
IPC分类号： C07F9/117 , C07F9/655
CPC分类号： C07F9/65515
摘要： The present invention relates to process for the preparation of fosamprenavir calcium.
摘要翻译：本发明涉及制备福沙那韦钙的方法。

5. 发明申请

US20120220786A1 PROCESS FOR THE PREPARATION OF FOSAMPRENAVIR CALCIUM 有权
标题翻译：制备FOSAMPRENAVIR钙的方法
公开(公告)号：US20120220786A1
公开(公告)日：2012-08-30
申请号：US13496281
申请日：2010-09-16
申请人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Kaptan Singh
发明人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Kaptan Singh
IPC分类号： C07F9/117
CPC分类号： C07F9/65515
摘要： The present invention relates to process for the preparation of fosamprenavir calcium.
摘要翻译：本发明涉及制备福沙那韦钙的方法。

6. 发明申请

US20120135965A1 AMORPHOUS FOSAMPRENAVIR CALCIUM 审中-公开
标题翻译：不育FOSAMPRENAVIR CALCIUM
公开(公告)号：US20120135965A1
公开(公告)日：2012-05-31
申请号：US13320991
申请日：2010-05-20
申请人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Anshul Agrawal , Kaptan Singh
发明人： Satish Manohar Bhoge , Prakash Kshirsagar , Santosh Richhariya , Anshul Agrawal , Kaptan Singh
IPC分类号： A61K31/665 , A61P31/18 , C07F9/655
CPC分类号： C07F9/65515 , A61K31/665 , A61K2300/00
摘要： The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith.
摘要翻译：本发明涉及无定形福桑那韦，其制备方法，包含该组合物的药物组合物和用于治疗HIV感染的方法。

7. 发明申请

US20060149054A1 Method for manufacture of ceftiofur 失效
标题翻译：头孢噻呋的制造方法
公开(公告)号：US20060149054A1
公开(公告)日：2006-07-06
申请号：US10532194
申请日：2003-10-27
申请人： Om Tyagi , Santosh Richhariya , Rajesh Pawar , Yuvaraj Chavan
发明人： Om Tyagi , Santosh Richhariya , Rajesh Pawar , Yuvaraj Chavan
IPC分类号： C07D501/14
CPC分类号： C07D417/14
摘要： A process for preparation of ceftiofur of formula (I) of high purity and substantially free from impurities is disclosed. The process comprises reacting [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II), with 7-amino-3-(2-furanylcarbonylthiomethyl)-3-cephem-4-carboxylic acid of formula (III) in the presence of a mixture of an water-immescible inert organic solvent and water and in the presence of a organic base and isolating ceftiofur of formula (I) substantially free of impurities by, d) adding water to the reaction mixture and selectively partitioning the impurities in the organic phase and ceftiofur (I) in the form of a salt with the base in the aqueous phase, e) acidifying the aqueous phase containing ceftiofur (I) in the form of a salt with the base in the presence of a mixture containing a water-miscible and a water-immiscible organic solvent and in the presence of a saturated aqueous solution of an alkali or alkaline earth containing salt, to partition ceftiofur (I) in the organic phase, and f) isolating ceftiofur (I) of high purity and substantially free of impurities by evaporation of the organic solvent or precipitation by addition of a co-solvent.
摘要翻译：公开了一种制备高纯度且基本上不含杂质的式（I）头孢噻呋的方法。该方法包括使式（II）的[2-（2-氨基噻唑-4-基）] - 2-顺式 - 甲氧基亚氨基乙酸-2-苯并噻唑基硫代酯与7-氨基-3-（2-呋喃基羰硫基甲基）-3 （III）的头孢-4-羧酸在水不溶性惰性有机溶剂和水的混合物存在下，在有机碱的存在下，分离基本上不含杂质的式（I）头孢噻呋， d）向反应混合物中加入水，并在水相中选择性地分配有机相中的杂质和与碱的盐形式的头孢噻呋（I），e）以含有头孢噻呋（I）的形式酸化含有头孢噻呋在含有水混溶性和与水不混溶的有机溶剂的混合物存在下，在含有碱或碱土金属盐的饱和水溶液的存在下，将碱与碱反应，从而将头孢噻吩（I）有机相，和f）分离高纯度和实质的头孢噻呋（I）通过蒸发有机溶剂或通过加入共溶剂沉淀而不含杂质。

8. 发明授权

US08536330B2 Intermediates for the preparation of HMG-CoA reductase inhibitors 失效
标题翻译：用于制备HMG-CoA还原酶抑制剂的中间体
公开(公告)号：US08536330B2
公开(公告)日：2013-09-17
申请号：US13642209
申请日：2011-04-21
申请人： Vishwesh Pravinchandra Pandya , Santosh Richhariya , Prabhakar Divya , Hashim Nizar Poovanathil Nagoor Meeran , Neera Tewari
发明人： Vishwesh Pravinchandra Pandya , Santosh Richhariya , Prabhakar Divya , Hashim Nizar Poovanathil Nagoor Meeran , Neera Tewari
IPC分类号： C07D417/12
CPC分类号： C07D417/12 , C07D239/26
摘要： The present invention provides a process for preparing novel intermediates of Formula wherein, R1 can be hydrogen, C1-C4 alkyl, halogen, nitro, hydroxy, or C1-C4 alkoxy; Rx can be selected from hydrophobic residue of HMG-CoA reductase inhibitors; which can be effectively used for the preparation of HMG-CoA reductase inhibitors such as rosuvastatin and pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供一种制备新型中间体的方法，其中R 1可以是氢，C 1 -C 4烷基，卤素，硝基，羟基或C 1 -C 4烷氧基; Rx可以选自HMG-CoA还原酶抑制剂的疏水残基; 其可以有效地用于HMG-CoA还原酶抑制剂如罗苏伐他汀及其药学上可接受的盐的制备。

9. 发明申请

US20130150579A1 NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS 失效
标题翻译：用于制备HMG-CoA还原酶抑制剂的新型中间体
公开(公告)号：US20130150579A1
公开(公告)日：2013-06-13
申请号：US13642209
申请日：2011-04-21
申请人： Vishwesh Pravinchandra Pandya , Santosh Richhariya , Prabhakar Divya , Hashim Nizar Poovanathil Nagoor Meeran , Neera Tewari
发明人： Vishwesh Pravinchandra Pandya , Santosh Richhariya , Prabhakar Divya , Hashim Nizar Poovanathil Nagoor Meeran , Neera Tewari
IPC分类号： C07D417/12 , C07D239/26
CPC分类号： C07D417/12 , C07D239/26
摘要： The present invention provides a process for preparing novel intermediates of Formula wherein, R1 can be hydrogen, C1-C4 alkyl, halogen, nitro, hydroxy, or C1-C4 alkoxy; Rx can be selected from hydrophobic residue of HMG-CoA reductase inhibitors; which can be effectively used for the preparation of HMG-CoA reductase inhibitors such as rosuvastatin and pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供一种制备新型中间体的方法，其中R 1可以是氢，C 1 -C 4烷基，卤素，硝基，羟基或C 1 -C 4烷氧基; Rx可以选自HMG-CoA还原酶抑制剂的疏水残基; 其可以有效地用于HMG-CoA还原酶抑制剂如罗苏伐他汀及其药学上可接受的盐的制备。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式